5h ago
SH PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
SH PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement or its accuracy.
or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.
Shanghai Pharmaceutical Group Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd. *
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 02607)
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
This is set forth on the website of Shanghai Stock Exchange (http://www.sse.com.cn) of Shanghai Pharmaceuticals Group Co., Ltd. (the "Company") Published "Shanghai Pharmaceutical Group Co., Ltd. Announcement on the Approval for Production of Rosuvastatin Ezetimibe Tablets (Ⅰ)",
"Shanghai Pharmaceutical Group Co., Ltd. About Dragon Tiger Cooling Oil Classic, Dragon Tiger Cooling Oil Powerful, and Dragon Tiger Roll-On Essential Oil"
Announcement on Obtaining Canadian Product License" is for reference only.
By order of the board of directors Shanghai Pharmaceutical Group Co., Ltd.
Yang Qiuhua Chairman
Shanghai, China, July 31, 2026 As at the date of this announcement, the executive directors of the Company are Mr. Yang Qiuhua, Mr. Shen Bo, Mr. Li Yongzhong and Mr. Dong Ming
Mr. Zhang; the non-executive director is Mr. Zhang Wenxue; the employee representative director is Mr. Zhao Yong; and the independent non-executive director The persons involved are Mr. Wang Zhong, Ms. Wan Jun, Mr. Xue Yunkui and Mr. Wang Qian.
*For identification only
Securities code: 601607 Securities abbreviation: Shanghai Pharmaceuticals No.: Lin 2026-059
Shanghai Pharmaceutical Group Co., Ltd.
Announcement on the approval for production of rosuvastatin and ezetimibe tablets ( ) Ⅰ The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.
or major omissions, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its content.
Recently, Changzhou Pharmaceutical Factory, a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company")
Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory") received approval from the State Food and Drug Administration (hereinafter referred to as "Changzhou Pharmaceutical Factory")
"Rosuvastatin Ezetimibe Tablets (Ⅰ) (hereinafter referred to as "the drug") issued by the National Food and Drug Administration"
"Drug Registration Certificate" (Certificate Number: 2026S02581), the drug is approved for production.
- Basic information about the drug
Drug name: Rosuvastatin Ezetimibe Tablets (Ⅰ)
Dosage form: tablet Specifications: Each tablet contains rosuvastatin calcium 10mg (calculated as C₂₂H₂₈FN₃O₆S) and ezetimibe 10mg
Registration classification: Chemicals Class 4
Drug approval number: National Drug Approval Number H20265225
Applicant: Changzhou Pharmaceutical Factory Co., Ltd.
Approval conclusion: According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product Comply with the relevant requirements for drug registration, approve the registration, and issue a drug registration certificate.
- Information related to the drug
Rosuvastatin and ezetimibe tablets are suitable for the treatment of hypercholesterolemia or homozygous familial hypercholesterolemia.
syndrome (HoFH), developed by Sanofi-aventis, S.R.O., and launched in the EU in July 2014. The product name is Zenon Neo. In December 2024, Changzhou Pharmaceutical Factory Co., Ltd. reported this drug to the State Food and Drug Administration
An application for registration and listing was submitted and accepted. As of the date of this announcement, the company has invested in research and development expenses for this drug.
Approximately RMB 9.68 million.
As of the date of this announcement, the main manufacturers of this drug in China are Shijiazhuang No.4 Pharmaceutical Co., Ltd., Zhejiang Pharmaceutical Co., Ltd.
Jiangnuode Pharmaceutical Co., Ltd., Beijing Fuyuan Pharmaceutical Co., Ltd., etc.
The IQVIA database shows that the purchase price of rosuvastatin and ezetimibe tablets for hospitals in mainland China in 2025
The amount is RMB 25.72 million.
- Impact on listed companies and risk warnings
According to relevant national policies, the varieties of generic drugs approved according to the new registration classification are subject to medical insurance payment and medical institutions.
Areas such as procurement will receive greater support. Therefore, Changzhou Pharmaceutical Factory’s rosuvastatin and ezetimibe tablets (Ⅰ) Obtaining approval for production will help expand the market share of the drug, enhance market competitiveness, and provide future prospects for the company.
We have accumulated valuable experience in carrying out generic drug declarations for continued products.
Due to the influence of national policies, market environment and other uncertain factors, the sales of this drug may not meet expectations.
Such situations are highly uncertain. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Shanghai Pharmaceutical Group Co., Ltd.
board of directors
July 31, 2026
Securities code: 601607 Securities abbreviation: Shanghai Pharmaceuticals No.: Lin 2026-060
Shanghai Pharmaceutical Group Co., Ltd.
About Longhu Cooling Oil Classic and Longhu Cooling Oil Powerful
and the announcement that Longhu Rolling Oil Essence has obtained a Canadian product license.
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.
or major omissions, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its content.
Recently, Shanghai Zhonghua Pharmaceutical, a subsidiary of Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company")
Co., Ltd. (hereinafter referred to as "Shanghai Zhonghua")'s classic Longhu Cooling Oil (Qingliang You) Regular), Qingliang Cooling Oil (Qingliang You Ultra), Qingliang Roll-on Oil Essence (Fengyou
Jing Oil) three products were officially approved by Health Canada’s Natural and Over-the-Counter Health Products Administration
Product license issued by (NNHPD). The relevant situation is now announced as follows:
- Basic information about the product
Name: Qingliang You Regular, Qingliang You Ultra, Fengyou Jing Oil
Dosage form: Ointment, Ointment, Oil
Product number: 80149973, 80149972, 80149974
Applicant: Shanghai Zhonghua Pharmaceutical Co., Ltd.
- Product-related information
The three products of Dragon Tiger Cooling Oil Classic, Dragon Tiger Cooling Oil Powerful, and Dragon Tiger Roll-On Essential Oil are mainly suitable for
For temporary relief of muscle and joint soreness/discomfort. In May 2026, Shanghai Pharmaceuticals China reported to Health Canada
Submit a product registration application to the Natural and OTC Health Products Authority. As of the date of this announcement, the company has
The product has been launched in Canada and has invested approximately RMB 49,500 in registration fees. As of the date of this announcement, the main cooling oil manufacturers in China are Luoyang Muchun Pharmaceutical Co., Ltd.;
The main manufacturers of Fengyoujing are Zhangzhou Shuixian Pharmaceutical Co., Ltd. Similar products marketed in Canada
Products include Haw Par Healthcare Limited’s Tiger Balm Red Strong, Tiger Balm White
Extra Strength.
Minai.com data shows that in 2025, cooling oil and Fengyoujing will be retailed in physical pharmacies and online stores in domestic cities.
The sales were RMB 95.79 million and RMB 478.72 million respectively.
- Impact on listed companies and risk warnings
This time, three products of Shanghai Pharmaceuticals China have obtained marketing authorization in Canada, which will help the company further expand overseas markets. It has positive significance and accumulates valuable experience.
The product export business is affected by changes in overseas market regulations, policies and market environment, exchange rate fluctuations, and market competition.
Affected by uncertain factors such as competition, sales may not meet expectations, etc., which is highly uncertain.
Investors are requested to invest rationally, make prudent decisions, and pay attention to investment risks.
Announcement is hereby made.
Shanghai Pharmaceutical Group Co., Ltd.
board of directors
July 31, 2026